Atsena Therapeutics
DURHAM, NC · Biotechnology · 38 employees
Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company’s lead program is evaluating ATSN-201 in an ongoing Phase 1 / 2 / 3 clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in lif
Funding history
- Funding Round — $90.0M — Apr 2025
- Series series c — $150.0M — Apr 2025
- Funding Round — $24.5M — Oct 2023
- Funding Round — $27.5M — Dec 2020
- Series seed — $4.1M — May 2020
Recent signals
- Jan 06, 2026: Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer
- Apr 11, 2025: Raised $90.0M
- Apr 03, 2025: Raised $150.0M in Series series c
- Oct 02, 2023: Raised $24.5M
- Dec 23, 2020: Raised $27.5M
- May 08, 2020: Raised $4.1M in Series seed
See plans & pricing → Track Atsena Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.